Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Have completed the SURMOUNT-5 study on study treatment
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52
Awards & highlights
Summary
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.
Eligible Conditions
- Obesity
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change from Baseline in Body Weight
Change from Baseline in Waist Circumference
Number of Participants Maintaining ≥80% of the Body Weight Reduction Achieved in SURMOUNT-5
+2 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: OrforglipronExperimental Treatment1 Intervention
Participants will receive orforglipron orally
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Orforglipron
2024
Completed Phase 1
~80
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,640 Previous Clinical Trials
3,222,718 Total Patients Enrolled
60 Trials studying Obesity
52,107 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,357 Previous Clinical Trials
419,824 Total Patients Enrolled
42 Trials studying Obesity
31,649 Patients Enrolled for Obesity
Share this study with friends
Copy Link
Messenger